Jens Eckstein

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands.

Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom.

Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom.

Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands.

Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.